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Abstract
Background: HIV infection, with an estimated prevalence be between 2 and 50 times those of the general adult
population is a major health challenge for prison authorities worldwide. Since no nationwide surveillance system is
present in Italy, data on HIV prevalence and treatment in prisons are limited to only a few and small observational
studies. We aimed to estimate HIV prevalence and obtain an overview on diagnostic and therapeutic activities
concerning HIV infection in the Italian penitentiary system.
Methods: We piloted a multi-centre cross-sectional study investigating the prevalence of HIV infection and
assessing HIV-related medical activities in Italian correctional institutions.
Results: A total of 15,675 prisoners from 25 institutions, accounting for approximately one-fourth of the prison
inmates in Italy, were included in the study, of whom, 97.7 % were males, 37.1 % foreigners and 27 % had a history
of intravenous drug addiction. HIV-tests were available in 42.3 % of the total population, with a known HIV Infection
proportion of 5.1 %. In the month prior to the study, 604 of the 1,764 subjects who entered prison were tested for
HIV, with a HIV-positive prevalence of 3.3 %. Among the 338 HIV-positive prisoners, 81.4 % were under antiretroviral
treatment and 73.5 % showed undetectable HIV-RNA. In 23/338 (6.8 %) a coinfection with HBV and in 189/338
(55.9 %) with HCV was also present. Among the 67 (19.8 %) inmates with HIV who did not receive HIV treatment,
13 (19.5 %) had T-CD4+ count <350 cells/mm3 and 9 (69.2 %) of these had refused the treatment. The majority of
the inmates with HIV-infection were on a PI-based (62.5 %) or on NNRTIs-based (24.4 %) regimen. Only a minority
of patients received once daily regimens (17.2 %).
Conclusions: Although clinical and therapeutic management of HIV infection remains difficult in Italian prisons,
diagnostics, treatment and care were offered to the majority of HIV-infected inmates. Specific programs should be
directed towards the prison population and strict cooperation between prison and health institutions is needed to
increase HIV treatment.
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Background
HIV is a major health challenge for prison authorities
worldwide. HIV prevalence within prisons is estimated
to be between 2 and 50 times those of general adult
populations. Available studies show an HIV prevalence
ranging from 0.6 % in the UK to 6 % in Spain and 7.2 %
in Italy [1–7].
In Italy measures promoting HIV prevention and con-
trol are listed among the health objectives that must be
guaranteed to the prison population. HIV tests cannot
take place without the consent of the person concerned
and may be recommended but not imposed on inmates
who display high risk behaviors. Detainees should be
informed with all relevant information concerning HIV
prevention. Counselling, treatment, care and support
services should be part of a comprehensive HIV pro-
gram aimed at improving health care in prison and at
making it equivalent to that available in the community
[8–10]. Nowadays, however, these objectives are largely
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unmet due to the limitations of the Italian penitentiary
system, such as severe budget constraints leading to
under-resourced prison settings, prison overcrowding,
poor condition of the existing health facilities, under-
trained and underpaid prison staffing, frequent inmate
transfer between prisons or prison wings, court attend-
ance and hospital visits, lack of a national correctional
healthcare database and especially the low offering and
execution of HIV screening [9–11].
Moreover, the data on treatment of HIV infection in
prisons are limited to only a few observational studies,
thus undermining current policy for improving prison
health care system [10–14].
The aims of this study were firstly, to evaluate the
prevalence of HIV infection among new entry inmates,
secondly, to evaluate the number of HIV infected
inmates who were actually treated and thirdly to
describe the antiretroviral treatments offered and report
the reasons for lack of treatment.
Methods
A multi-centre cross-sectional survey was carried out
from 1 to 30 July 2013 to investigate the prevalence of
HIV infection and to assess HIV-related diagnostic and
therapeutic activities in Italian correctional institutions.
The prevalence of HIV infection was estimated in the
imprisoned population on July 31, 2013. Data on HIV
testing was evaluated both in the entire prison popula-
tion and in the prison entrants during the study period.
A questionnaire was emailed to the 206 Italian prisons
and was voluntarily completed by health professionals
based in the prison establishments using information in
medical records. The following data was recorded only
for inmates who were present during the study period:
general data (sex, ethnicity and drug use), HIV data
(HIV testing, viro-immunological profile, visit schedule),
HIV treatment data (setting, method, frequency of drug
dispensation, type of antiretrovirals used, medication
refusal). Returned surveys were collected and consolidated
using build-in functions of Microsoft Excel. Where gaps in
the questionnaire data remained, prison administrative
bodies and experts were contacted via e-mail or telephone
and requests for specific information were made.
All studies regarding the Italian Penitentiary System have
been nationally approved by the Ethics Committee of the
University of Rome Tor Vergata (Registro Sperimentazioni
73/05). No specific consent was required since data were
collected in anonymous and aggregate form.
Statistical analysis
Data was analyzed using the SPSS statistical software,
version 6.0. Results are expressed as proportions. When
applicable, a two-tailed hypothesis testing for difference
in proportions was used (Proportion Test); a p value
of <0.05 was considered significant.
Results
Prison population in Italy
On 31 July 2013 Italian prisons counted 64,873 detainees,
almost one per 1,000 inhabitants. Foreign detainees were
22,744. It is worth noting that foreign prisoners had more
than doubled between 1990 (15 %) and 2013 (35 %). At
the time of the study, Italy’s prisons were the most
crowded in the European Union with occupancy at more
than 142 % of capacity.
Survey population
On July 31, a total of 15,675 prisoners (15,318 males and
357 females) were included in the survey, accounting for
24.2 % of the total Italian inmates. Thirty-five of the 206
correctional institutions in Italy from 16 of the 20 Italian
regions voluntarily answered the questionnaire: 12 in
Northern Italy (n = 6,527 inmates), 11 in Central Italy
(n = 3,846 inmates) and 12 in Southern Italy (n = 5,302
inmates). The number of prisoners included in the survey
ranged from 7.8 % to 69.1 % according to geographical
area. Overall, the institutes in Northern Italy accounted
for nearly one-third (32.7 %) of the prisoners included in
the survey, compared with 21.5 % in Central Italy and
22.7 % in Southern Italy. During the month prior to the
survey 1,764 adults were imprisoned. Table 1 shows the
characteristics of inmates entered into the study, accord-
ing to Italian region. The majority of prisoners were men
(97.7 %) with native born Italians accounting for 62.9 % of
inmates and foreigners 37.1 % (range 2.0 % - 88.0 %). The
vast majority of foreign prisoners included individuals
from Morocco (19.0 %), Romania (15.8 %), Albania
(12.5 %), Tunisia (12.1 %), Nigeria (4.2 %), Algeria (2.6 %),
Egypt (2.0 %) and Senegal (1.8 %). Just under one-third of
prison inmates (27.0 %) had a history of heroin or cocaine
misuse.
HIV and other infectious diseases testing
Among the participating penitentiary institutions, 35/35
(100 %) performed screening tests for HIV, HBV and
HCV, 27/35 (77.1 %) for tuberculosis and 31/35 (88.6 %)
for syphilis.
A voluntary HIV screening, as part of routine clinical
evaluations, was available in 6,630 (42.3 %) of the total
population at the time of the study and 338 (5.1 %), 330
(97.6 %) males and 8 (2.4 %) females, of these inmates
were HIV-infected. Among the 338 HIV-infected in-
mates 266/338 (78.7 %) were Italian, 72/338 (21.3 %)
were foreigners, 23/338 (6.8 %) were also HBsAg-
positive and 189/388 (55.9 %) had anti-HCV antibodies.
Regarding risk factors for HIV infection, 175/338
(51.7 %) reported being intravenous drug users (IVDU),
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16/338 (4.7 %) were men having sex with men (MSM)
and 147/338 (43.5 %) declared sexual contact risk.
Furthermore, 85/163 (52.1 %) of non IVDU reported
tattooing or body piercing with unsterile equipment.
When considering only the 72 HIV-infected foreigners,
49/72 (68.0 %) reported being IVDU, 20/72 (27.8 %)
were heterosexuals and 3/72 (4.2 %) were MSM.
When considering only the 1,764 subjects incarcerated
during the month prior to the survey, HIV-test was of-
fered to 1,338 (75.8 %) at prison entry and 604 (45.1 %)
of these accepted to be tested, 417 (31.2 %) refused, 276
(20.6 %) were waiting for the results and 41 (3.1 %) were
not tested due to their release. Among the 604 tested
inmates, 20 (3.3 %) were HIV-Ab positive.
Viro-immunological characteristics of treated patients
All the institutions provided information regarding ac-
cess to viro-immunological parameters while in prison.
Viral load measurement was performed in all of them,
lymphocytes subsets immunophenotyping in 94.3 % and
genotypic testing for HIV in 74.3 %.
An evaluation of the clinical data of 338 HIV-infected
inmates, showed that 81.4 % were receiving an
antiretroviral treatment (ART) and that 73.5 % showed
an undetectable HIV-RNA (<50 copies/mL).
Fewer than 10 % of the detained patients on therapy,
had CD4 lymphocyte counts below 200/mm3 (9.4 %),
18.2 % had between 200/mm3 and 349/mm3, 32.0 %
between 350/mm3 and 500/mm3, and 36.4 % above
500/mm3. CD4 lymphocyte count was not available in
4 % of the inmates. By contrast, among the 67 inmates
(19.8 %) who were not on ART, less than 5 % of the pris-
oners had CD4 lymphocyte counts below 200/mm3
(4.5 %), 15.0 % between 200/mm3 and 349/mm3, 10.4 %
between 350/mm3 and 500/mm3, and 70.1 % had CD4
above 500/mm3. CD4 lymphocyte count was not available
for 4 % of these patients.
HIV treatment and care
The majority of known HIV-positive inmates (275/338;
81.4 %) were receiving antiretroviral treatment at the
time of the study. Of them, 172/275 (62.5 %) were re-
ceiving a protease inhibitor (PI)-based ART, 72 (21.0 %) a
non-nucleoside reverse transcriptase inhibitors (NNRTIs)-
based ART and 27 (9.8 %) raltegravir as an integrase
inhibitor-based ART. The difference in the proportion of



















Abruzzo 7 0 2047 0 0 0 0
Basilicata 3 0 483 0 0 0 0
Calabria 12 2 2651 744 (36.3 %) 696 (93.5 %) 105 (14.1 %) 161 (21.6 %)
Campania 17 4 7999 3230 (40.4 %) 3230 (100 %) 867 (26.8 %) 422 (13.1 %)
Emilia Romagna 13 5 3759 1570 (41.8 %) 1507 (100 %) 545 (36.2 %) 861 (54.8 %)
Friuli Venezia Giulia 5 1 845 275 (32.5 %) 275 (100 %) 59 (21.4 %) 172 (62.5 %)
Lazio 14 1 7175 739 (10.3 %) 739 (100 %) 197 (26.6 %) 259 (35.0 %)
Liguria 7 1 1764 240 (13.6 %) 240 (100 %) 100 (41.7 %) 105 (43.8 %)
Lombardia 19 3 8961 1869 (20.8 %) 1868 (99.9 %) 633 (33.9 %) 644 (34.5 %)
Marche 7 1 1108 300 (27.1 %) 279 (93.0 %) 63 (21.0 %) 138 (46.0 %)
Molise 3 0 505 0 0 0 0
Piemonte 13 2 4870 1760 (36.1 %) 1,660 (94.3 %) 346 (19.6) 694 (39.4 %)
Puglia 12 1 4039 428 (10.6 %) 408 (95.3 %) 94 (21.9 %) 120 (28.0 %)
Sardegna 12 1 2095 165 (7.8 %) 148 (89.6 %) 78 (47.2 %) 44 (26.6 %)
Sicilia 26 3 6976 735 (10.5 %) 735 (100 %) 161 (21.9 %) 130 (17.7 %)
Toscana 18 3 4135 733 (17.7 %) 733 (100 %) 232 (31.6 %) 271 (37.0 %)
Trentino Alto Adige 3 1 405 280 (69.1 %) 260 (92.8 %) 50 (17.8 %) 224 (80.0 %)
Umbria 4 2 1672 504 (30.1 %) 504 (100 %) 120 (23.8 %) 201 (39.9 %)
Valle d’Aosta 1 0 278 0 0 0 0
Veneto 10 4 3106 2103 (67.7 %) 2036 (96.8 %) 582 (27.7 %) 1377 (65.5 %)
National Total 206 35 64,873 15,675 (24.2 %) 15,318 (97.7 %) 4232 (27.0 %) 5761 (36.7 %)
Monarca et al. BMC Infectious Diseases  (2015) 15:562 Page 3 of 8
patients treated patients with PI-based regimens com-
pared to those receiving NNRTIs-based regimens was
statistically significant (p < 0.005).
PI-based antiretroviral regimens included atazanavir in
88 (32.0 %) patients, lopinavir (18.5 %) in 51, darunavir
in 23 (8.4 %), fosamprenavir in 9 (3.3 %) and saquinavir
in 1 (0.4 %), as shown in Table 2.
NNRTI-based ART regimens included efavirenz in 50
(18.2 %) patients, nevirapine in 9 (3.3 %), rilpivirine in 8
(2.9 %), and etravirine in 5 (1.8 %). In 41/50 (82 %)
patients efavirenz was included in the efavirenz-
tenofovirdisoproxilfumarate-emtricitabine co-formulation
and in 6/8 (75 %) rilpivirine was part of the rilpivirine-
tenofovirdisoproxilfumarate-emtricitabine co-formulation
(Table 2).
The backbone in the 275 HIV-positive inmates consisted
of 194 (70.5 %) tenofovirdisoproxilfumarate-emtricitabine,
41 (14.9 %) abacavir-lamivudine, 12 lamivudine-zidovudine
(4.4 %), and 28 (10.2 %) other NRTI combinations (Table 2).
The medical visit schedule was on weekly basis in 4.3 %
of prisoners under ART, on monthly basis in 32.9 %, on
quarterly basis in 51.4 % and every 6 months in 11.4 %.
All the correctional institutes had medical facilities able
to dispense antiretroviral drugs. Lack of HIV treatment in
prisoners with CD4 lymphocyte count < 350/mm3 was
due to medication refusal (69.2 %), ongoing medical as-
sessment (23.1 %) and other reasons including fear of side
effects, cultural or ethnic beliefs, depression or delusional
state (7.7 %).
Medication dispensing by nurse practitioners to those
who were under ART occurred in prison (70 %) or at the
medical unit (30 %). The methods for dispensing medica-
tions were: daily directly observed therapy (DOT, 42.8 %),
keep-on-person (KOP, 31.4 %) with daily delivery and a
mixed combination (25.7 %). Frequency of dispensing was
once a day (17.2 %), twice a day (31.4 %) or ≥ 3 times a day
(51.4 %). Once a day regimens were perceived to facilitate
DOT by a majority (65.7 %) of the healthcare staff with
only 25.7 % considering these regimens useless to DOT.
After prison release, nearly two-thirds (66.4 %) of the
prisoners were followed up by infectious disease specialists.
Discussion
This study was designed to provide a current picture of
HIV prevalence, treatment and care in the Italian prison
population.
The lack of a comprehensive surveillance system makes it
difficult to estimate the prevalence of HIV-infected inmates
in the Italian correctional system. Published prevalence data
are usually taken from studies conducted on small numbers
of prisons or in single regions, this hampering the achieve-
ment of definite data. Likewise, little is known about treat-
ment of HIV among inmates [7, 10, 11, 14]. Medical
assistance to HIV-infected individuals is a relevant issue in
the community of inmates and treatment monitoring is
essential to guarantee an appropriate use of antiretroviral
drugs and high quality patient care [7, 10, 15–18]. Point-
prevalence studies based on existing medical data in cor-
rectional institutes could help to better understand the
spread of HIV as well as elaborate successful prevention
and care strategies.
Although our findings are limited by the partial par-
ticipation of the Italian penal institutes, they contribute
to improve our knowledge on HIV infection, treatment
and care among HIV-patients detained in Italy. In fact,
with more than 15,000 inmates in 35 prisons distributed
all over the country, our investigation includes nearly
one-quarter of those incarcerated in Italy, with 27.0 %
being IVDU and 37.1 % being foreigners at the time of
the study.
Looking at the distribution of the participating prisons
across the country and at the composition of HIV-risk
factors among inmates, our data seems to be reasonably
representative of the Italian prison population.
Despite the low rate of HIV testing identified in our
study and the well-known difficulty in inmate patients to
Table 2 Antiretroviral regimens received by the 275
HIV-infected inmates on ART
ANTIRETROVIRAL DRUGS n (%)
Protease inhibitors (PI)
Atazanavir 88 (32.0 %)
Lopinavir 51 (18.5 %)
Darunavir 23 (8.4 %)
Fosamprenavir 9 (3.3 %)
Saquinavir 1 (0.4)
Total 172 (62.6 %)
Non nucleoside reverse trascriptase inhibitors (NNRTI)
Efavirenz 50 (18.2 %)
Nevirapine 9 (3.3 %)
Rilpivirine 8 (2.9 %)
Etravirine 5 (1.8 %)
Total 72 (26.2 %)
3 Nucleoside reverse transriptase inhibitors (NRTI)
Abacavir-Lamivudine-Zidovudine 6 (2.2 %)
Integrase inhibitors (INI)
Raltegravir 24 (8.7 %)
CCR5 inhibitors
Maraviroc 1 (0.4 %)
NRTI backbone
Tenofovir disoproxilfumarate-emtricitabine 194 (70.5 %)
Abacavir-lamivudine 41 (14.9 %)
Zidovudine-lamivudine 12 (4.4 %)
Other 28 (10.2 %)
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admit their disease condition, we found an HIV preva-
lence above 5 % which is more than 12 times higher
than in the general Italian population [19, 20].
This discrepancy was also confirmed in newly admit-
ted prisoners (HIV testing rate 34.2 %, HIV prevalence
3.3 %) and underline that prisons are concentrators of
infectious diseases, due also to higher risk behaviours in
acquiring blood born viruses (BBV) in people likely to
be incarcerated. In our study we show an high rate of
IVDU and tattoing/body piercing among both Italian
and foreign BBV-infected inmates. For these reasons, the
imprisonment period should be considered as an oppor-
tunity to treat a hard-to-reach population in freedom
[21–27]. Finally, we cannot exclude the possibility that
the real prevalence of HIV infection might have been
underestimated by the low rate of testing.
Some findings deserve attention in our study. Firstly,
foreign detainees represent 37.1 % of prisoners, the vast
majority coming from low and middle-income countries
where the health burden imposed by HIV is further ex-
acerbated by poor socioeconomic conditions, the high
prevalence of opportunistic infections, poor access to
health care, and widespread drug circulation and abuse.
Secondly, Italian prison population contains nearly one-
third of prisoners with a history of drug misuse at some
time in their lives. Given the interplay between transmis-
sible diseases, drug use, low-to middle-income countries
origin and incarceration, there is a need to develop ap-
proaches to increase the acceptance of testing by raising
an awareness in prisoners regarding infections, Appropriate
testing pathways in prison should be optimized to ensure
adequate pre- and post-test discussion, and to develope
care pathways that enable treatment in prison as well as
continuity of care upon release [28–32]. It is essential that
prison healthcare personnel, in particular infectious
disease specialists, make every effort to increase the offer
of HIV screening in prison; indeed, the knowledge of HIV
status among inmates is the only condition for HIV
prisoners to access antiretroviral drugs and to obtain con-
tinuity of care when released [31, 32].
Moreover, we found a high proportion of patients with
concomitant chronic viral hepatitis caused by HBV in
6.8 % and by HCV in 55.9 %. Patients with HBV coinfec-
tion should start antiretroviral therapy active also against
HBV. The very high proportion of patients with HCV
coinfection could represent a probably unique option to
treat these patients. With the introduction of all-oral
anti HCV directly-acting antiviral (DAA) drug com-
binations that eliminate interferon and its side effects,
treatment uptake outside the prison setting is rapidly
increasing. Some of these combination regimens have
achieved sustained virologic response (SVR) in more than
90 % of some subgroups in clinical trials, including null
responders to prior interferon-based treatment [33, 34].
Current evidence suggest that HIV/HCV co-infected can
achieve the same percentage of response as HCV mono-
infected [35]. The prison setting, with the possibility of
DOT also for HCV, could represent a key option in order
to obtain HCV eradication and reduce the progres-
sion of liver disease for the single patient as well as
reducing the chance of transmission inside or, outside
prison, after release.
Even in a prison setting, standard-of-care strategies
have showed that health outcomes among HIV-infected
inmates improve significantly. It is well established that
the availability of combination antiretroviral therapy in
prison is largely responsible for decreased AIDS-related
mortality and morbidity among inmates in the recent
years in high-income countries [33–38]. Our study
shows that the vast majority of the known HIV-infected
inmates were under therapy often taken with daily DOT.
Successful HIV suppression was shown in over 72 % of
treated patients who had an undetectable HIV-RNA.
Nevertheless, several obstacles to HIV treatment in pri-
son still remain. High costs, difficulties in maintaining
confidentiality, lack of trust in correctional staff as well
as the social dynamics of correctional facilities are all
implicated as barriers to HIV treatment, as suggested by
our findings.
We found that almost two out of three of the treated
prisoners were given PI-based regimens compared to
nearly one in four who received NNRTIs-based combin-
ation. Most patients probably then continue the regi-
mens they receive in the community setting. The choice
of PI-based HAART is probably due to the perceived
low adherence by the physician in freedom and the high
proportion of PI-based schedules is the continuation of
ongoing treatment. However, when considering organi-
zation problems in prison, together with the need to
treat prisoners with complex behaviors in a problematic
context, caregivers should aim at reducing pill burden
and dosing frequency [32, 37, 39–42]. The availability of
single tablet regimens with good forgiveness can be an
option that combines efficacy, safety and low pill burden
giving the opportunity to the patients to continue such
combinations even after incarceration [39–49]. It is thus
mandatory to remember that regimen simplification can
be implemented only if the suppression of HIV-RNA is
ensured. Simplification can be a useful approach not
only to reach successful viro-immunological outcomes
among prisoners under HIV treatment, but also to
improve the patient’s quality of life, maintain long-term ad-
herence, avoid toxicities that may develop with prolonged
ARTand reduce the risk of virologic failure [50–52].
Although we found that over 80 % of HIV-infected in-
mates were treated for HIV with more than 70 % with
undetectable viral load in the Italian correctional insti-
tutes, this finding does not account for the needs of
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infected unaware prisoners. Nearly 67 % of patients not
receiving HAART at the time of the study had a CD4
cell count <350 cells/mm3, which represents the recog-
nized threshold for therapy initiation in all international
guidelines. This data highlights the need for the phys-
ician working in prison to be more proactive in con-
vincing patients to start HAART since there is a clear
benefit in term of morbidity and mortality reduction
[36–40]. The persistence of unprotected sexual relations
as well as the injection of drugs without sterile
equipment or with needle sharing during incarceration
strengthens even more the need to test and treat HIV-
infected inmates in order to reduce virus transmission,
as observed in other settings [53–57].
Upon release only approximately two-third of the pris-
oners were followed up by infectious disease specialists.
The loss to follow up of one-third of patients highly
stresses the need to integrate HIV prevention and treat-
ment services both outside and within correctional insti-
tutions. The integration of care should include access to
medical discharge planning and referral to community-
based HIV care providers, both being of utmost im-
portance to guarantee continuity of care when inmates
are released back into the community [58–64].
Treating HIV-infected inmates poses significant chal-
lenges, but there are several obstacles to the proper in-
take of anti-HIV drugs, not only due to patients. Prison
doctors may be wary of managing complicated treatment
regimens which often have adverse side effects, espe-
cially in high-risk populations such as IVDU. Inadequate
prison infrastructures are a significant barrier to imple-
menting comprehensive HIV care in Italy. Problems
occur with patient non compliance, medical contraindi-
cations and high medication costs. Finally, inmates may
be reluctant to seek testing and treatment because of
fear, denial or distrust of the competence of correctional
medical staff.
Conclusions
HIV treatment in Italian prisons is not uniform and this
undermines the ability to provide high-quality care for
the inmates infected with HIV. Diagnostics, treatment
and care are offered to the majority of HIV-infected
inmates, but the costs of not treating a part of this popu-
lation could be significantly higher. Prisons should rep-
resent an integral part of strategies to slow down the
HIV and possibly the HCV epidemic through the suc-
cessful treatment of infected inmates and missed oppor-
tunities for treatment could have negative consequences
not only on the incarcerated population, but on society
as a whole. Therefore, nationwide programs, integrated
with the National Health System, should be imple-
mented to increase the quality of care in Italian prisons
and encourage linkage to care after prison release.
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